Core Viewpoint - The company, 瑞立科密, is experiencing an increase in overseas sales revenue, which is expected to account for approximately 16% of its main business revenue in 2024 [1] Group 1 - The company is strengthening its efforts in expanding overseas customer relationships [1] - The overseas sales revenue for the company in 2024 is projected to be 31,172.91 million yuan [1] - The proportion of overseas sales revenue in relation to the main business revenue is on the rise [1]

Core Viewpoint - The company Jinli Permanent Magnet has received approval for general licenses from the Ministry of Commerce, which is expected to impact its export operations positively [1] Group 1: Company Performance - For the first three quarters of 2025, the company achieved overseas sales revenue of 942 million yuan, remaining stable compared to the same period last year [1] - The sales revenue from exports to the United States reached 354 million yuan, representing a year-on-year increase of 43.92% [1] Group 2: Regulatory Developments - The company noted that it and two other enterprises have obtained the first batch of general licenses, although it refrained from commenting further and advised stakeholders to refer to official announcements [1]

Core Viewpoint - Haofan Bio (301393) reported that its overseas sales revenue for 2024 is projected to account for 22.13% from Asia, 10.04% from Europe, and 4.09% from America of the total operating revenue [1] Group 1: Company Overview - The main products of the company are specialty chemical raw materials primarily based on peptide synthesis reagents, positioned upstream in the pharmaceutical industry chain [1] - The company offers a wide range of products and serves thousands of customers annually, demonstrating strong risk resistance capabilities [1] Group 2: Market Expansion - The company established a wholly-owned subsidiary in Germany in January 2025, targeting CDMO and formulation clients in the European market to further expand its business in Europe [1]